These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31905381)

  • 1. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
    Rens NE; Uyl-de Groot CA; Goldhaber-Fiebert JD; Croda J; Andrews JR
    Clin Infect Dis; 2020 Dec; 71(12):3136-3143. PubMed ID: 31905381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rapid Pharmacogenomic Assay to Detect
    Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
    [No Abstract]   [Full Text] [Related]  

  • 3. Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India.
    Khan N; Das A
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):443-447. PubMed ID: 35349098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
    Am J Respir Crit Care Med; 2024 Jun; 209(12):1486-1496. PubMed ID: 38647526
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
    Lee J; Choi G; Yang S; Ha JE; Kim ES; Park JS; Lee K; Song J; Lee JH; Lee JI
    Tuberculosis (Edinb); 2021 Mar; 127():102052. PubMed ID: 33548864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
    Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis.
    Hemanth Kumar AK; Ramesh K; Kannan T; Sudha V; Haribabu H; Lavanya J; Swaminathan S; Ramachandran G
    Indian J Med Res; 2017 Jan; 145(1):118-123. PubMed ID: 28574024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India.
    Bahuguna P; Prinja S; Lahariya C; Dhiman RK; Kumar MP; Sharma V; Aggarwal AK; Bhaskar R; De Graeve H; Bekedam H
    Appl Health Econ Health Policy; 2020 Jun; 18(3):393-411. PubMed ID: 31741306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
    Masiphephethu MV; Sariko M; Walongo T; Maro A; Mduma D; Gratz J; Alshaer M; Peloquin CA; Mduma E; Mpagama SG; Thomas T; Houpt ER; Traore A; Bessong P; Heysell SK; Operario DJ
    Tuberculosis (Edinb); 2022 Sep; 136():102246. PubMed ID: 35961094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
    Leung VC; Pechlivanoglou P; Chew HF; Hatch W
    Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
    Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
    Naidoo A; Chirehwa M; Ramsuran V; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ncgapu S; Adamson J; Govender K; Denti P; Padayatchi N
    Pharmacogenomics; 2019 Mar; 20(4):225-240. PubMed ID: 30767706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
    Zhu R; Kiser JJ; Seifart HI; Werely CJ; Mitchell CD; D'Argenio DZ; Fletcher CV
    J Clin Pharmacol; 2012 Apr; 52(4):511-9. PubMed ID: 21558457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
    Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
    BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.